Apolipoprotein A-I mimetics and high-density lipoprotein function

Scott M. Gordon, William S. Davidson

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


PURPOSE OF REVIEW: To review recently published advances in the development of apolipoprotein A-I (apoA-I) mimetic peptides as a potential treatment for cardiovascular diseases. RECENT FINDINGS: Various apoA-I mimetic peptides are currently in development and these display potent cardioprotective features that can rival or even surpass those of full length apoA-I and high-density lipoproteins (HDLs). These features include the ability to efflux cholesterol from various cell types as well as anti-inflammatory and antioxidative properties. Recent work has been aimed at identifying the structural features of these peptides that are responsible for these various functions and also for determining the operational mechanisms. There is also interesting new data suggesting that the intestine may be playing an important role in the action of these peptides. SUMMARY: In the last year, there have been many important advances in the relatively new field of apoA-I mimetic therapy. These findings support a strong potential for their development as treatment for not only cardiovascular disease but other disease states involving chronic inflammation and oxidation as well.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number2
StatePublished - Apr 2012


  • apolipoprotein A-I
  • atherosclerosis
  • high-density lipoprotein
  • mimetic peptide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'Apolipoprotein A-I mimetics and high-density lipoprotein function'. Together they form a unique fingerprint.

Cite this